{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342388","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2026-08-10T20:10:39+00:00","discovered_at":"2026-08-10T20:12:01.530848+00:00","generated_at":"2026-08-10T20:12:28.869052+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Metagenomi Q2 2026: $120.7M cash, IND for MGX-001 hemophilia A on track for 4Q 2026","bullets":["Cash, equivalents, and marketable securities $120.7M as of June 30, 2026; runway through 4Q 2027.","IND application for MGX-001 (hemophilia A) on track for 4Q 2026; IND-enabling studies expected complete by end of Q3 2026.","R&D expenses flat at $22.5M YoY; G&A down to $6.0M from $7.0M in Q2 2025.","Two scientific posters won Top Poster Awards at 2026 ISTH Congress in Paris.","Plans to initiate clinical trials in 2027 subject to regulatory clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342388","json":"https://secwatch.observer/filing/0001193125-26-342388.json","markdown":"https://secwatch.observer/filing/0001193125-26-342388.md","text":"https://secwatch.observer/filing/0001193125-26-342388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/0001193125-26-342388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:12:28.869052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}